A5089777309- Dialysis and Renal Disease Management
- Central Venous Catheters and Hemodialysis
- Parathyroid Disorders and Treatments
- Acute Kidney Injury Research
- Acute Myeloid Leukemia Research
- Health Systems, Economic Evaluations, Quality of Life
- Electrolyte and hormonal disorders
- Epigenetics and DNA Methylation
- Hemoglobinopathies and Related Disorders
- Urological Disorders and Treatments
- Heart Rate Variability and Autonomic Control
- PI3K/AKT/mTOR signaling in cancer
- Renal function and acid-base balance
- Traditional Chinese Medicine Studies
- Urinary Bladder and Prostate Research
- Lung Cancer Treatments and Mutations
- Potassium and Related Disorders
- TGF-β signaling in diseases
- Thermoregulation and physiological responses
- Ginseng Biological Effects and Applications
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Iron Metabolism and Disorders
- Autoimmune Bullous Skin Diseases
- Lipid metabolism and disorders
Hexi University
2024
Second Affiliated Hospital of Chongqing Medical University
2024
Dalian Medical University
2024
Chongqing Medical University
2024
Wuhan University
2024
Wenzhou Medical University
2024
Anhui University of Traditional Chinese Medicine
2023
Shanghai Jiao Tong University
2008-2022
Renji Hospital
2004-2013
Jiangsu University
2009
Importance Tongxinluo, a traditional Chinese medicine compound, has shown promise in vitro, animal, and small human studies for myocardial infarction, but not been rigorously evaluated large randomized clinical trials. Objective To investigate whether Tongxinluo could improve outcomes patients with ST-segment elevation infarction (STEMI). Design, Setting, Participants Randomized, double-blind, placebo-controlled trial was conducted among STEMI within 24 hours of symptom onset from 124...
Background. The impact of dialysis modality on the rates and types infectious complications has not been well studied. aim present investigation was to evaluate hepatitis C virus (HCV) B (HBV) infections in peritoneal (PD) haemodialysis (HD) patients Asia-Pacific region. Methods. study included most recent period-prevalent data recorded national or regional registries 10 countries/areas (Australia, New Zealand, Japan, China, Taiwan, Korea, Thailand, Hong Kong, Malaysia India), where such...
Renal replacement therapy is rapidly expanding in China, and two-times weekly dialysis common, but detailed data on practice patterns are currently limited. Using cross-sectional from the China Dialysis Outcomes Practice Patterns Study (DOPPS), we describe hemodialysis compared with other DOPPS countries, examining demographic, social clinical characteristics of patients dialysis. The protocol was implemented 2011 among a cross-section 1379 45 facilities Beijing, Guangzhou Shanghai. Data...
While a low-protein diet may preserve residual renal function (RRF) in chronic kidney disease (CKD) patients before the start of dialysis, high-protein intake is usually recommended dialysis to prevent protein-energy wasting. Keto acids, which were often pre-dialysis CKD treated with diet, had also been reported be associated both RRF and nutrition maintenance. We conducted randomized trial test whether or without keto acids would safe preserved during peritoneal (PD).To assess safety low...
Objective. We compared patient characteristics, dialysis practice patterns and outcomes of peritoneal (PD) patients between one Chinese centre Canadian to determine whether observed differences in demographics practices are associated with technique survival.
Maintenance dialysis therapy is the only way to remove excess fluid in patients with anuric end-stage renal disease. The optimal ultrafiltration (UF) volume on peritoneal (PD) remains controversial.We retrospectively analysed a cohort of 86 prevalent PD followed up for median 25.3 months (range, 6 54 months). Clinical and parameters were recorded yearly. Kaplan-Meier analysis Cox proportional hazards models used identify risk factors mortality technique failure UF >/=1 L/24 h or <1 h.When...
Several studies by microarray analysis and real-time polymerase chain reaction (RT-PCR) reveal that type I interferon-inducible genes (IFIGs) are implicated in systemic lupus erythematosus (SLE). To find a potential clinical biomarker capable of monitoring disease activity clinically, quantitative RT-PCR was used to identify transcript expression levels 13 IFIGs peripheral blood cells 144 patients with SLE, 27 non-SLE 60 healthy controls then analyse connections between gene activity. The...
Objective As high glucose (HG) concentration in peritoneal dialysis (PD) solution is thought to contribute fibrosis, and angiotensin II receptor blockers (ARBs) may have a key role preventing fibrosis as they inhibit the TGF- ß1–Smad pathway, aims of this vitro study were investigate 1) if HG affects expression Smad human mesothelial cells (HPMCs) 2) ARB (losartan) can effect. Methods HPMCs, obtained from non-renal patients undergoing elective abdominal surgery, stimulated by solutions with...
Background: This study aimed to identify the impact of prior cancer on overall survival (OS) patients with osteosarcoma and describe their characteristics then establish a nomogram. Procedure: Data diagnosed between 2010 2015 were extracted from Surveillance, Epidemiology, End Results database. The difference was balanced by propensity score matching. Kaplan–Meier Cox analyses performed evaluate influence cancer. Patients randomly divided into training cohort testing cohort. A nomogram for...
Ultrasound-guided prostate biopsy is a reliable diagnostic procedure for cancer diagnosis with minimal procedure-related trauma. However, complications, such as massive rectal bleeding may occur after the puncture. We hypothesized that using transrectal resectoscope could help treat punctures.
e14504 Background: Linifanib (ABT-869) is an orally bioavailable, potent, VEGF/PDGF RTK inhibitor. Activity was observed in a phase II trial of pts with HCC (ASCO 2010, abstr 4038). An exploratory analysis who received linifanib for >48 weeks (wk) presented. Methods: This open-label, multicenter 0.25 mg/kg QD Child-Pugh A (CPA) or QOD B until progressive disease (PD) intolerable toxicity, ongoing. Eligibility criteria include ≤1 prior systemic treatment and ≥1 measurable lesions by CT scan....